Key result
Regulatory guidance for Non Biologic Complex Drugs (NBCDs) such as iron-carbohydrate drugs and low molecular weight heparins is lacking, necessitating a new regulatory framework.
Answers are grounded in this paper and cite their sources.
The paper highlights the need for a new regulatory framework for Non Biologic Complex Drugs (NBCDs) like iron sucrose and low molecular weight heparins, as the standard generic paradigm is insufficient.
When the patent of a small molecule drug expires, generics may be introduced. They are considered therapeutically equivalent once pharmaceutical equivalence (i.e. identical active substances) and bioequivalence (i.e. comparable pharmacokinetics) have been established in cross-over volunteer study. However this generic paradigm cannot be applied to complex drugs as biologics. For copies of biologics EMA, and FDA, have introduced a new regulatory bio-similar pathway which mandate clinical trials to show therapeutic equivalence. However for some complex drugs, such as iron-carbohydrate drugs, low molecular weight heparins (named Non Biologic Complex Drugs [NBCD]), regulatory guidance is still mostly lacking. In this paper we will discuss therapeutic experiences with these different classes of complex drugs and their specificity, to provide scientific arguments for consideration for a new regulatory framework.
No takes yet. Share an insight, caveat, or question.
Jacques Rottembourg (2014) reported a review. Non Biologic Complex Drugs (NBCD) was evaluated. Regulatory guidance for Non Biologic Complex Drugs (NBCDs) such as iron-carbohydrate drugs and low molecular weight heparins is lacking, necessitating a new regulatory framework.
Synapse has enriched 10 related papers. Consider them for comparative context: